Comparative Pharmacology
Head-to-head clinical analysis: TROVAN PRESERVATIVE FREE versus VIGAMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TROVAN PRESERVATIVE FREE versus VIGAMOX.
TROVAN PRESERVATIVE FREE vs VIGAMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting bacterial DNA replication and transcription.
Fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, preventing bacterial DNA replication.
200 mg intravenously once daily.
1 drop in affected eye(s) every 4 hours while awake for 7 days; may increase to 1 drop every 2 hours on day 1.
None Documented
None Documented
Terminal elimination half-life is approximately 10–13 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life: 12-14 hours; clinically relevant for once-daily dosing
Renal excretion accounts for approximately 90% of elimination, with ~50% as unchanged drug. Fecal/biliary excretion accounts for the remaining ~10%.
Renal: 70-80% unchanged; biliary/fecal: 15-20%
Category C
Category C
Antibiotic (Fluoroquinolone)
Antibiotic (Fluoroquinolone)